# A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

> **NCT04725331** · PHASE1,PHASE2 · TERMINATED · sponsor: **Transgene** · enrollment: 31 (actual)

## Conditions studied

- Metastatic Cancer
- Soft Tissue Sarcoma
- Merkel Cell Carcinoma
- Melanoma
- Triple Negative Breast Cancer
- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** BT-001
- **DRUG:** Pembrolizumab [KEYTRUDA®]

## Key facts

- **NCT ID:** NCT04725331
- **Lead sponsor:** Transgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-25
- **Primary completion:** 2025-10-22
- **Final completion:** 2025-10-22
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Sponsor decision following completion of Phase I part not driven by safety reason
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725331, "A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04725331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*